KRTX News and Press, Karuna Therapeutics Inc. From 08/03/20

Topline results of exploratory trial do not provide conclusive evidence of an analgesic benefit of KarXT on experimentally induced pain in healthy volunteers The Company will not move forward to evaluate KarXT for the treatment of pain The safety and tolerability profile of KarXT ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Biotech Pulse Biotechs continue to be one of the leading healthcare groups and along with diagnostics represent two of the best segments of healthcare. The first half saw biotechs recover quicker from the March selloff than most of the market, and reach a milestone that took 5 years to achie...

Multi-year drug discovery collaboration leveraging behavioral and physiological phenotypic screening and machine learning to identify novel neuropsychiatric drug candidates Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to dev...

Karuna Therapeutics (NASDAQ: KRTX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We had the opportunity to host investor meetings with the management team of Karuna Therapeutics, including CEO Steve Paul and CFO Troy Ignezi. A...

Karuna Therapeutics Reports Positive News for Acute Psychosis Treatment Karuna Therapeutics, Inc. ( KRTX ) reported that it plans to proceed with its clinical program assessing KarXT for the treatment of acute psychosis in patients with schizophrenia. The company stated that it has compl...

Fresh off a meeting with the FDA, Karuna Therapeutics (NASDAQ: KRTX ) will advance lead candidate KarXT into Phase 3 development for the treatment of acute psychosis in patients with schizophrenia. More news on: Karuna Therapeutics, Inc., Healthcare stocks news, Read more ...

One additional Phase 3 trial, along with previously completed Phase 2 trial, would be acceptable to support an efficacy claim for a New Drug Application filing Company on track to initiate Phase 3 program, including efficacy and open-label long-term safety trials, by the end of 2...

Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Pau...